Nano Biosols links up with Shimyatech in nano based anti viral project         September 2020

Shimyatech Ltd, a Liverpool based nanotech  R and D company has won funding from the Liverpool City Regions Future Investment Fund to develop antiviral applications targeting COVID-19.  They are developing unique nanocomposite materials to prevent surface contamination and therefore minimise virus transfer between people. Nano Biosols have entered into an agreement to collaborate on this project.

Nano Biosols has worked closely with Shimyatech in the past  in  our joint effort to create a nano-hub of commercial nanotech activity on Merseyside. Our aim is to find solutions to real world problems, particularly in the application of nanotech to the life sciences  and healthcare.

Read all about it here

NANO BIOSOLS LATERAL FLOW PLUSTM KIT VALIDATED BY iiCON.            Sept. 2021                  

Lateral Flow PlusTM  , a novel method and kit, now patent pending, was developed by Nano Biosols  to improve the sensitivity of Covid 19 lateral flow tests due to their perceived lack of sensitivity compared to PCR. The reagent is applied to the assay cassette after the initial assay if the result is negative or  very faint. The kit improves sensitivity at least tenfold (LOD 0.1 ng/ml).  Several of the commercial lateral flow tests used in the UK during the pandemic were amplified by tenfold on stated sensitivities. The kit amplifies the gold signal and so is disease agnostic and can be applied to any gold based test for any analyte. The kit has been independently validated by iiCON, the Infection and Innovation Consortium unit at the Liverpool School of Tropical Medicine. Nano Biosols is open to any manufacturer of lateral flow tests whom wish to discuss collaborations to see how the kit may improve their products.